IP Library Granted Patent US 9,700,511
Granted Patent B2
US 9,700,511 · App. 14/774,833 · Granted Jul 11, 2017

Controlled drug release liposome composition

Inventors: Pei Kan (Taipei, TW); Yun-Long Tseng (Taipei, TW); Han Chun Ou (Taipei, TW)
Assignees: TLC Biopharmaceuticals, Inc.; Taiwan Liposome Company, Ltd.
A61K9/127A61K31/337A61K31/475A61K31/4745A61K31/704A61K31/7048Y10S977/907
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,700,511
App. No.
14/774,833
Granted
Jul 11, 2017
Kind
B2
Abstract

The present invention relates to a pharmaceutical composition comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent. The present invention also relates to methods of inhibiting cancer cell growth, comprising administering the pharmaceutical composition described herein.

Claims (7)

1. A pharmaceutical composition, comprising:

at least one liposome having a particle forming component selected from a phospholipid or a mixture of at least one phospholipid and cholesterol;

0.1 mM to 3.0 mM dextran sulfate or a pharmaceutically acceptable salt thereof;

100 mM to 400 mM ammonium sulfate or a pharmaceutically acceptable salt thereof; and

vinorelbine.

2. The pharmaceutical composition of claim 1 , wherein the liposome further comprises a hydrophilic polymer with a long chain of highly hydrated flexible polymer attached to a phospholipid molecule.

3. The pharmaceutical composition of claim 1 , wherein dextran sulfate has a molecular weight about 1,600 daltons to about 8,000 daltons.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2015
From: KAN, PEI; TSENG, YUN-LONG; OU, HAN CHUN
To: TLC BIOPHARMACEUTICALS, INC.; TAIWAN LIPOSOME COMPANY, LTD
Reel/Frame 036540/0927 →
Continuity (2)
Provisional Application 61792850 · Mar 15, 2013
Related Publication 20160030340A1 · Feb 4, 2016